Cancer Biomarkers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Description

The global cancer biomarkers market is poised for significant growth and expansion in the upcoming years. Cancer biomarkers play a crucial role in early detection, diagnosis, and cancer monitoring applications by indicating the presence of cancer cells in the body. The market is witnessing remarkable progress, driven by the alarming rise in cancer incidence and the continuous demand for personalized medicine. Various types of biomarkers, including genetic, proteomic, and glycomic biomarkers, contribute to the market's diversity. Despite some challenges such as high costs of biomarker tests and lack of standardization in biomarker development and validation, continuous research and development efforts are expected to sustain market growth momentum.

Non-invasive Diagnostic Tools Drive Healthy Growth Prospects

The demand for non-invasive diagnostic tools has seen significant growth, outpacing traditional procedures like biopsies. The rising activism surrounding cancer prevalence and early detection methods has underscored the importance of cancer biomarkers in cancer detection and diagnosis. This trend presents vast opportunities for players in the cancer biomarkers market. According to Fairfield Market Research, the global cancer biomarkers market is projected to reach a valuation of over US$26 billion by 2025, maturing at a healthy CAGR over the same period. These figures illustrate the abundance of opportunities available in the market, attracting substantial investments.

Technological Advancements and Rising Cancer Prevalence Fuel Market Expansion

The increasing burden of cancer on patients and healthcare professionals has heightened the need for precise and efficient diagnostic tools. Ongoing technological advancements have paved the way for discovering novel biomarkers, leading to improved accuracy and treatment of cancer. Innovations in genomics and proteomics have facilitated the identification of specific genetic and protein biomarkers associated with different types of cancer, fostering the development of targeted and personalized therapies. In response to current trends in cancer treatment, governments and private entities are making significant investments in research and development and upgrading healthcare infrastructure. The confluence of these factors is set to drive the growth trajectory of the global cancer biomarkers industry.

North America Leads Amid Ongoing Technological Innovations

North America is expected to maintain its leadership position in the global cancer biomarkers market. Established industry players focusing on advanced biomarker development and robust healthcare infrastructure that embraces novel solutions are driving market growth in the region. The market also benefits from the higher prevalence of cancer cases in the region. Additionally, Europe and the Asia Pacific regions are displaying healthy growth prospects, supported by the availability of diagnostic technologies, burgeoning healthcare infrastructure, and increasing awareness of early cancer detection and diagnostic techniques.

Key Market Players Driving Growth

Leading industry participants spearheading growth in the global cancer biomarkers market include: Thermo Fisher Scientific, Abbott Laboratories, Illumina Inc., Roche Diagnostics, and Qiagen N.V. These players are strategically engaging in collaborations, acquisitions, and partnerships to maintain their market positions and contribute to the advancement of cancer diagnosis and treatment.

As the global cancer biomarkers market continues its stride towards holistic growth, innovations in diagnostic tools and personalized therapies are poised to make a significant impact on cancer management and patient outcomes.

1. Executive Summary

1.1. Global Cancer Biomarkers Market Snapshot
1.2. Key Market Trends
1.3. Future Projections
1.4. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
  - 2.2.1.1. Driver A
  - 2.2.1.2. Driver B
  - 2.2.1.3. Driver C
- 2.2.2. Restraints
  - 2.2.2.1. Restraint 1
  - 2.2.2.2. Restraint 2
- 2.2.3. Market Opportunities Matrix
2.3. Porter's Five Forces Analysis
2.4. Covid-19 Impact Analysis
2.5. Regulatory Framework
2.6. PESTLE

3. Global Cancer Biomarkers Market Outlook, 2018 - 2030

3.1. Global Cancer Biomarkers Market Outlook, by Biomarker Type, Value (US$ Mn), 2018 - 2030
- 3.1.1. Key Highlights
  - 3.1.1.1. Protein
  - 3.1.1.2. Genetic
  - 3.1.1.3. Other
3.2. Global Cancer Biomarkers Market Outlook, by Testing Method, Value (US$ Mn), 2018 - 2030
- 3.2.1. Key Highlights
  - 3.2.1.1. Tissue Biopsy
  - 3.2.1.2. Liquid Biopsy
- 3.2.2. BPS/Market Attractiveness Analysis
3.3. Global Cancer Biomarkers Market Outlook, by Cancer Type, Value (US$ Mn), 2018 - 2030
- 3.3.1. Key Highlights
  - 3.3.1.1. Lung
  - 3.3.1.2. Prostate
  - 3.3.1.3. Breast
  - 3.3.1.4. Colorectal
  - 3.3.1.5. Gastric
  - 3.3.1.6. Leukemia
  - 3.3.1.7. Other
- 3.3.2. BPS/Market Attractiveness Analysis
3.4. Global Cancer Biomarkers Market Outlook, by Application, Value (US$ Mn), 2018 - 2030
- 3.4.1. Key Highlights
  - 3.4.1.1. Screening
  - 3.4.1.2. Differential Diagnosis
  - 3.4.1.3. Treatment Selection
  - 3.4.1.4. Treatment Monitoring
  - 3.4.1.5. Other
3.5. Global Cancer Biomarkers Market Outlook, by Region, Value (US$ Mn), 2018 - 2030
- 3.5.1. Key Highlights
  - 3.5.1.1. North America
  - 3.5.1.2. Europe
  - 3.5.1.3. Asia Pacific
  - 3.5.1.4. Latin America
  - 3.5.1.5. Middle East & Africa
- 3.5.2. BPS/Market Attractiveness Analysis

4. North America Cancer Biomarkers Market Outlook, 2018 - 2030

4.1. North America Cancer Biomarkers Market Outlook, by Biomarker Type, Value (US$ Mn), 2018 - 2030
- 4.1.1. Key Highlights
  - 4.1.1.1. Protein
  - 4.1.1.2. Genetic
  - 4.1.1.3. Other
4.2. North America Cancer Biomarkers Market Outlook, by Testing Method, Value (US$ Mn), 2018 - 2030
- 4.2.1. Key Highlights
  - 4.2.1.1. Tissue Biopsy
  - 4.2.1.2. Liquid Biopsy
4.3. North America Cancer Biomarkers Market Outlook, by Cancer Type, Value (US$ Mn), 2018 - 2030
- 4.3.1. Key Highlights
  - 4.3.1.1. Lung
  - 4.3.1.2. Prostate
  - 4.3.1.3. Breast
  - 4.3.1.4. Colorectal
  - 4.3.1.5. Gastric
  - 4.3.1.6. Leukemia
  - 4.3.1.7. Other
4.4. North America Cancer Biomarkers Market Outlook, by Application, Value (US$ Mn), 2018 - 2030
- 4.4.1. Key Highlights
  - 4.4.1.1. Screening
  - 4.4.1.2. Differential Diagnosis
  - 4.4.1.3. Treatment Selection
  - 4.4.1.4. Treatment Monitoring
  - 4.4.1.5. Other
4.5. North America Cancer Biomarkers Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
- 4.5.1. Key Highlights
  - 4.5.1.1. U.S.
  - 4.5.1.2. Canada
- 4.5.2. BPS/Market Attractiveness Analysis

5. Europe Cancer Biomarkers Market Outlook, 2018 - 2030

5.1. Europe Cancer Biomarkers Market Outlook, by Biomarker Type, Value (US$ Mn), 2018 - 2030
- 5.1.1. Key Highlights
  - 5.1.1.1. Protein
  - 5.1.1.2. Genetic
  - 5.1.1.3. Other
5.2. Europe Cancer Biomarkers Market Outlook, by Testing Method, Value (US$ Mn), 2018 - 2030
- 5.2.1. Key Highlights
  - 5.2.1.1. Tissue Biopsy
  - 5.2.1.2. Liquid Biopsy
5.3. Europe Cancer Biomarkers Market Outlook, by Cancer Type, Value (US$ Mn), 2018 - 2030
- 5.3.1. Key Highlights
  - 5.3.1.1. Lung
  - 5.3.1.2. Prostate
  - 5.3.1.3. Breast
  - 5.3.1.4. Colorectal
  - 5.3.1.5. Gastric
  - 5.3.1.6. Leukemia
  - 5.3.1.7. Other
5.4. Europe Cancer Biomarkers Market Outlook, by Application, Value (US$ Mn), 2018 - 2030
- 5.4.1. Key Highlights
  - 5.4.1.1. Screening
  - 5.4.1.2. Differential Diagnosis
  - 5.4.1.3. Treatment Selection
  - 5.4.1.4. Treatment Monitoring
  - 5.4.1.5. Other
5.5. Europe Cancer Biomarkers Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
- 5.5.1. Key Highlights
  - 5.5.1.1. Germany
  - 5.5.1.2. France
  - 5.5.1.3. U.K.
  - 5.5.1.4. Italy
  - 5.5.1.5. Spain
  - 5.5.1.6. Russia
  - 5.5.1.7. Rest of Europe
- 5.5.2. BPS/Market Attractiveness Analysis

6. Asia Pacific Cancer Biomarkers Market Outlook, 2018 - 2030

6.1. Asia Pacific Cancer Biomarkers Market Outlook, by Biomarker Type, Value (US$ Mn), 2018-2030
- 6.1.1. Key Highlights
  - 6.1.1.1. Protein
  - 6.1.1.2. Genetic
  - 6.1.1.3. Other
6.2. Asia Pacific Cancer Biomarkers Market Outlook, by Testing Method, Value (US$ Mn), 2018 - 2030
- 6.2.1. Key Highlights
  - 6.2.1.1. Tissue Biopsy
  - 6.2.1.2. Liquid Biopsy
6.3. Asia Pacific Cancer Biomarkers Market Outlook, by Cancer Type, Value (US$ Mn), 2018 - 2030
- 6.3.1. Key Highlights
  - 6.3.1.1. Lung
  - 6.3.1.2. Prostate
  - 6.3.1.3. Breast
  - 6.3.1.4. Colorectal
  - 6.3.1.5. Gastric
  - 6.3.1.6. Leukemia
  - 6.3.1.7. Other
6.4. Asia Pacific Cancer Biomarkers Market Outlook, by Application, Value (US$ Mn), 2018 - 2030
- 6.4.1. Key Highlights
  - 6.4.1.1. Screening
  - 6.4.1.2. Differential Diagnosis
  - 6.4.1.3. Treatment Selection
  - 6.4.1.4. Treatment Monitoring
  - 6.4.1.5. Other
6.5. Asia Pacific Cancer Biomarkers Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
- 6.5.1. Key Highlights
  - 6.5.1.1. China
  - 6.5.1.2. Japan
  - 6.5.1.3. South Korea
  - 6.5.1.4. India
  - 6.5.1.5. Southeast Asia
  - 6.5.1.6. Rest of Asia Pacific
- 6.5.2. BPS/Market Attractiveness Analysis

7. Latin America Cancer Biomarkers Market Outlook, 2018 - 2030

7.1. Latin America Cancer Biomarkers Market Outlook, by Biomarker Type, Value (US$ Mn), 2018 - 2030
- 7.1.1. Key Highlights
  - 7.1.1.1. Protein
  - 7.1.1.2. Genetic
  - 7.1.1.3. Other
7.2. Latin America Cancer Biomarkers Market Outlook, by Testing Method, Value (US$ Mn), 2018-2030
- 7.2.1. Key Highlights
  - 7.2.1.1. Tissue Biopsy
  - 7.2.1.2. Liquid Biopsy
7.3. Latin America Cancer Biomarkers Market Outlook, by Cancer Type, Value (US$ Mn), 2018 - 2030
- 7.3.1. Key Highlights
  - 7.3.1.1. Lung
  - 7.3.1.2. Prostate
  - 7.3.1.3. Breast
  - 7.3.1.4. Colorectal
  - 7.3.1.5. Gastric
  - 7.3.1.6. Leukemia
  - 7.3.1.7. Other
7.4. Latin America Cancer Biomarkers Market Outlook, by Application, Value (US$ Mn), 2018 - 2030
- 7.4.1. Key Highlights
  - 7.4.1.1. Screening
  - 7.4.1.2. Differential Diagnosis
  - 7.4.1.3. Treatment Selection
  - 7.4.1.4. Treatment Monitoring
  - 7.4.1.5. Other
7.5. Latin America Cancer Biomarkers Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
- 7.5.1. Key Highlights
  - 7.5.1.1. Brazil
  - 7.5.1.2. Mexico
  - 7.5.1.3. Rest of Latin America
- 7.5.2. BPS/Market Attractiveness Analysis

8. Middle East & Africa Cancer Biomarkers Market Outlook, 2018 - 2030

8.1. Middle East & Africa Cancer Biomarkers Market Outlook, by Biomarker Type, Value (US$ Mn), 2018 - 2030
- 8.1.1. Key Highlights
  - 8.1.1.1. Protein
  - 8.1.1.2. Genetic
  - 8.1.1.3. Other
8.2. Middle East & Africa Cancer Biomarkers Market Outlook, by Testing Method, Value (US$ Mn), 2018 - 2030
- 8.2.1. Key Highlights
  - 8.2.1.1. Tissue Biopsy
  - 8.2.1.2. Liquid Biopsy
8.3. Middle East & Africa Cancer Biomarkers Market Outlook, by Cancer Type, Value (US$ Mn), 2018 - 2030
- 8.3.1. Key Highlights
  - 8.3.1.1. Lung
  - 8.3.1.2. Prostate
  - 8.3.1.3. Breast
  - 8.3.1.4. Colorectal
  - 8.3.1.5. Gastric
  - 8.3.1.6. Leukemia
  - 8.3.1.7. Other
8.4. Middle East & Africa Cancer Biomarkers Market Outlook, by Application, Value (US$ Mn), 2018 - 2030
- 8.4.1. Key Highlights
  - 8.4.1.1. Screening
  - 8.4.1.2. Differential Diagnosis
  - 8.4.1.3. Treatment Selection
  - 8.4.1.4. Treatment Monitoring
  - 8.4.1.5. Other
8.5. Middle East & Africa Cancer Biomarkers Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
- 8.5.1. Key Highlights
  - 8.5.1.1. GCC
  - 8.5.1.2. South Africa
  - 8.5.1.3. Rest of Middle East & Africa
- 8.5.2. BPS/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Company Market Share Analysis
9.2. Competitive Dashboard
9.3. Company Profiles
- 9.3.1. Illumina
  - 9.3.1.1. Company Overview
  - 9.3.1.2. Product Portfolio
  - 9.3.1.3. Financial Overview
  - 9.3.1.4. Business Strategies and Development
- 9.3.2. Roche Diagnostics
- 9.3.3. Qiagen N.V.
- 9.3.4. Bio-Rad Laboratories, Inc.
- 9.3.5. Myriad Genetics
- 9.3.6. Angle PLC
- 9.3.7. Guardant Health
- 9.3.8. Exact Sciences Corporation
- 9.3.9. Thermo Fisher Scientific
- 9.3.10. Abbott Laboratories
- 9.3.11. Inviate Corporation
- 9.3.12. Other

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations